Viewing data from:

DEPO-ESTRADIOL

ANDA

ESTRADIOL CYPIONATE | A085470 | PFIZER INC

3 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Depo-Estradiol (2023)

Total Spending

$681K

Total Claims

3,429

Beneficiaries

1,893

Avg Cost/Unit

$34.13

Spending Trend

$1.1M(2019)→$1.2M(2020)→$1.2M(2021)→$780K(2022)→$681K(2023)

YoY Change:+23.9%

5yr CAGR:+12.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Medicare Part B Spending

CMS physician-administered drug spending for Depo-Estradiol (2023)

Total Spending

$104K

Total Claims

3,969

Beneficiaries

826

ASP Price

—

HCPCS: J1000 — Injection, depo-estradiol cypionate, up to 5 mg

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

API Supply Chain1 active DMF2 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

PHARMACIA AND UPJOHN CO WHOLLY OWNED SUB PFIZER INCESTRADIOL CYPIONATE USP

DMF 50471983

DIOSYNTH BVInactiveESTRADIOL CYPIONATE

DMF 29921977

DIOSYNTH INCInactiveESTRADIOL CYPIONATE

DMF 38331980

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 1MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.

#002 — 3MG/ML

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982

#003 — 5MG/ML

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982